TFFP - Dosing underway TFF Pharma's mid-stage study with inhaled voriconazole

TFF Pharmaceuticals ([[TFFP]] -1.0%) has dosed the first asthma subjects in its Phase 1b trial of voriconazole, direct to lung inhaled dry powder. This study in patients with asthma will assess the safety, pharmacokinetics, and induction of bronchospasm.The company is also advancing development of Voriconazole inhalation powder towards a pivotal Phase 2 study to assess the efficacy of the dry powder formulation for the treatment of Invasive Pulmonary Aspergillosis.TFFP's proprietary Thin Film Freezing technology platform allows the reformulation of voriconazole into dry powder particles with properties believed to be suited for inhalation delivery. In addition to voriconazole, TFF is also developing dry powder formulations of tacrolimus to prevent lung transplant rejection and niclosamide to treat COVID-19 (SARS-CoV2) infections.

For further details see:

Dosing underway TFF Pharma's mid-stage study with inhaled voriconazole